scispace - formally typeset
Open AccessJournal ArticleDOI

Long‐term follow‐up of febrile infection–related epilepsy syndrome

Reads0
Chats0
TLDR
The features of the chronic epilepsy are described and critically review evidence for the etiology of this syndrome is critically reviewed.
Citations
More filters
Journal ArticleDOI

Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases.

TL;DR: Cannabidiol is added as a possible treatment for febrile infection-related epilepsy syndrome who had not responded to antiepileptic drugs or other therapies who were given cannabadiol on emergency or expanded investigational protocols in either the acute or chronic phase of illness.
Journal ArticleDOI

Febrile Infection-Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis.

TL;DR: It is hypothesized that FIRES is an immune but not an autoimmune disease and discussed GABAergic therapy at high doses, avoidance of burst-suppression coma, and early introduction of enteral or even parenteral ketogenic diet as the most promising treatment.
Journal ArticleDOI

New onset refractory status epilepticus (NORSE).

TL;DR: This review presents the rare but devastating syndrome of NORSE, including the subcategory of FIRES, and suggests early recognition with complete work-up is primordial to identify the underlying cause and promptly start appropriate treatment.
Journal ArticleDOI

Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome

TL;DR: It is shown that treatment with the recombinant interleukin‐1 (IL1) receptor antagonist anakinra results in down-regulation in the production and function of endogenous IL1RA in patients with FIRES.
References
More filters
Journal ArticleDOI

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

TL;DR: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotRexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Journal ArticleDOI

Defining criteria for autoimmune diseases (Witebsky's postulates revisited)

TL;DR: In this article, three types of evidence can be marshalled to establish that a human disease is autoimmune in origin: direct evidence from transfer of pathogenic antibody or pathogenic T cells; indirect evidence based on reproduction of the autoimmune disease in experimental animals; and circumstantial evidence from clinical clues.
Journal ArticleDOI

Nav1.1 Localizes to Axons of Parvalbumin-Positive Inhibitory Interneurons: A Circuit Basis for Epileptic Seizures in Mice Carrying an Scn1a Gene Mutation

TL;DR: The authors' data indicate that Nav1.1 plays critical roles in the spike output from PV interneurons and, furthermore, that the specifically altered function of these inhibitory circuits may contribute to epileptic seizures in the mice.
Journal ArticleDOI

An open label study of the effects of rituximab in neuromyelitis optica

TL;DR: Eight patients with worsening neuromyelitis optica were treated with rituximab to achieve B cell depletion and seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up.
Related Papers (5)